With the Fed Minutes in toe, Wall Street is at ease once again. Warren and her reserve committee have decided, yet again, to leave rates right where they are for now. They highlighted the increasing economic growth but also cited that we may not exactly be quite there when it comes to the ability to increase interest rates from where they rest today. This saw relatively flat sentiment in the markets if not slightly green by the end of the day with the Dow closing up roughly 15 points and the S&P 500 up just under 3 points. As this was the case, several other equities saw massive increases in stock price and volume during the Wednesday morning session. These include Altisource Asset Management Corp (NYSEMKT:AAMC), Iddriven Inc (OTCMKTS:IDDR), and ITUS Corp (NASDAQ:ITUS)
Altisource Asset Management Corp (NYSEMKT:AAMC), reported a second quarter loss roughly 2 months ago. The asset management corporation saw a dramatic decline in stock price from $130 per share to levels nearing $10. Over recent weeks, the stock price has been increasing significantly and over the more recent trading days this week, shares of Altisource have jumped to highs of nearly $50/share; almost a 400% increase in stock price within just a few weeks.
Don’t Miss Another winner like this, Login to The #1 Stock Chat Online Today. Best Part? It’s totally free and no need to pay any sign-up fee. Click Here http://bit.ly/2dqhpyH
Iddriven Inc (OTCMKTS:IDDR) has had a banner month of September, which has continued into the first few weeks of October. The stock managed to open the month around $0.14 and has seen highs this week of $0.23 marking a move of over 60% in just a few weeks. The company’s recent announcement of the release of its IDdriven 2.0 has seen the volatility of the stock increase since last week. On Wednesday the stock spiked to highs of $0.224 and reach as low as $0.135. Shares of IDDR were able to rebound back by the end of the day to $0.1899.
ITUS Corp (NASDAQ:ITUS) hit highs of $6.49 on Wednesday. The stock has been climbing since late September after it had announced several demonstrations of efficacy in multiple forms of cancer that include colon cancer, melanoma,ovarian cancer, liver cancer and most recently, thyroid cancer. The company’s Ccheck™ early cancer detection system has received much more notice along the way for these kinds of developments. The stock is up more than 125% since September’s $2.85 lows.
Have you made a choice to find real opportunity in the stock market? Join a winning team and find breakout alerts like these BEFORE the street, Login now: http://bit.ly/2dqhpyH